{"id":19279,"date":"2026-02-03T19:20:39","date_gmt":"2026-02-03T22:20:39","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/"},"modified":"2026-02-03T19:20:39","modified_gmt":"2026-02-03T22:20:39","slug":"artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/","title":{"rendered":"ARTEMIDE-Lung04 &#8211; CPCNP metast\u00e1tico, PD-L1 \u2265 50% &#8211; 1\u00aa linha"},"content":{"rendered":"<div>Avaliar efic\u00e1cia e seguran\u00e7a de rilvegostomig em compara\u00e7\u00e3o a pembrolizumabe.<\/div>\n<div aria-hidden=\"true\">&nbsp;<\/div>\n<div><b>Popula\u00e7\u00e3o:<\/b><\/div>\n<ul>\n<li>\u226518 anos;<\/li>\n<li>CPCNPm est\u00e1gio IV;<\/li>\n<li>Express\u00e3o de PD-L1 no tumor em \u2265 50%;<\/li>\n<li>Aus\u00eancia de muta\u00e7\u00f5es sensibilizantes do EGFR e rearranjos de ALK e ROS1, al\u00e9m de outras muta\u00e7\u00f5es acion\u00e1veis para as quais haja terapias de 1L direcionadas aprovadas localmente;<\/li>\n<li>Peso corporal m\u00ednimo de 30 kg;<\/li>\n<li>ECOG 0 a 1.<\/li>\n<\/ul>\n<p>ClinicalTrials.gov:&nbsp;NCT06868277<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avaliar efic\u00e1cia e seguran\u00e7a de rilvegostomig em compara\u00e7\u00e3o a pembrolizumabe. &nbsp; Popula\u00e7\u00e3o: \u226518 anos; CPCNPm est\u00e1gio IV; Express\u00e3o de PD-L1 no tumor em \u2265 50%; Aus\u00eancia de muta\u00e7\u00f5es sensibilizantes do EGFR e rearranjos de ALK e ROS1, al\u00e9m de outras muta\u00e7\u00f5es acion\u00e1veis para as quais haja terapias de 1L direcionadas aprovadas localmente; Peso corporal m\u00ednimo [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19279","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ARTEMIDE-Lung04 - CPCNP metast\u00e1tico, PD-L1 \u2265 50% - 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-\u2265-50-1a-linha\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARTEMIDE-Lung04 - CPCNP metast\u00e1tico, PD-L1 \u2265 50% - 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Avaliar efic\u00e1cia e seguran\u00e7a de rilvegostomig em compara\u00e7\u00e3o a pembrolizumabe. &nbsp; Popula\u00e7\u00e3o: \u226518 anos; CPCNPm est\u00e1gio IV; Express\u00e3o de PD-L1 no tumor em \u2265 50%; Aus\u00eancia de muta\u00e7\u00f5es sensibilizantes do EGFR e rearranjos de ALK e ROS1, al\u00e9m de outras muta\u00e7\u00f5es acion\u00e1veis para as quais haja terapias de 1L direcionadas aprovadas localmente; Peso corporal m\u00ednimo [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-\u2265-50-1a-linha\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\\\/\",\"name\":\"ARTEMIDE-Lung04 - CPCNP metast\u00e1tico, PD-L1 \u2265 50% - 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2026-02-03T22:20:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"ARTEMIDE-Lung04 &#8211; CPCNP metast\u00e1tico, PD-L1 \u2265 50% &#8211; 1\u00aa linha\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARTEMIDE-Lung04 - CPCNP metast\u00e1tico, PD-L1 \u2265 50% - 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-\u2265-50-1a-linha\/","og_locale":"pt_BR","og_type":"article","og_title":"ARTEMIDE-Lung04 - CPCNP metast\u00e1tico, PD-L1 \u2265 50% - 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Avaliar efic\u00e1cia e seguran\u00e7a de rilvegostomig em compara\u00e7\u00e3o a pembrolizumabe. &nbsp; Popula\u00e7\u00e3o: \u226518 anos; CPCNPm est\u00e1gio IV; Express\u00e3o de PD-L1 no tumor em \u2265 50%; Aus\u00eancia de muta\u00e7\u00f5es sensibilizantes do EGFR e rearranjos de ALK e ROS1, al\u00e9m de outras muta\u00e7\u00f5es acion\u00e1veis para as quais haja terapias de 1L direcionadas aprovadas localmente; Peso corporal m\u00ednimo [&hellip;]","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-\u2265-50-1a-linha\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/","name":"ARTEMIDE-Lung04 - CPCNP metast\u00e1tico, PD-L1 \u2265 50% - 1\u00aa linha - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2026-02-03T22:20:39+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/artemide-lung04-cpcnp-metastatico-pd-l1-%e2%89%a5-50-1a-linha\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"ARTEMIDE-Lung04 &#8211; CPCNP metast\u00e1tico, PD-L1 \u2265 50% &#8211; 1\u00aa linha"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}